&lt;p&gt;Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study&lt;/p&gt;

Chen, Hong; Zhu, Hongxia; Yu, Xiang‐Nan; Shi, Xuan; Bilegsaikhan, Enkhnaran; Guo, Huimin; Huang, Ruoyu; Liu, Taotao; Shen, Xizhong; Zhu, Ji‐Min

doi:10.2147/cmar.s192241

Cited by 5 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that from the top 50 HepG2 secreted proteins, Gastricsin and Glypican-3 were not detected in the secretome of PHH (Table S1). Gastricsin was recently postulated to play a tumorigenesis role in the progression of hepatocellular carcinoma (HCC) [39]. Glypican-3 is among the most promising candidates for early diagnostic markers of HCC [40].…”

Section: Discussionmentioning

confidence: 99%

Identification of the Secreted Proteins Originated from Primary Human Hepatocytes and HepG2 Cells

et al. 2019

View full text Add to dashboard Cite

The liver plays a pivotal role in whole-body carbohydrate, lipid, and protein metabolism. One of the key regulators of glucose and lipid metabolism are hepatokines, which are found among the liver secreted proteins, defined as liver secretome. To elucidate the composition of the human liver secretome and identify hepatokines in primary human hepatocytes (PHH), we conducted comprehensive protein profiling on conditioned medium (CM) of PHH. Secretome profiling using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-MS/MS) identified 691 potential hepatokines in PHH. Subsequently, pathway analysis assigned these proteins to acute phase response, coagulation, and complement system pathways. The secretome of PHH was compared to the secreted proteins of the liver hepatoma cell line HepG2. Although the secretome of PHH and HepG2 cells show a high overlap, the HepG2 secretome rather mirrors the fetal liver with some cancer characteristics. Collectively, our study represents one of the most comprehensive secretome profiling approaches for PHH, allowing new insights into the composition of the secretome derived from primary human material, and points out strength and weakness of using HepG2 cell secretome as a model for the analysis of the human liver secretome.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of the Secreted Proteins Originated from Primary Human Hepatocytes and HepG2 Cells

et al. 2019

View full text Add to dashboard Cite

show abstract

“…12 The expression of pepsinogen C in gastric cancer was able to identify subgroups of patients with different clinical outcomes. 13 However, to date, only one tissue microarray study reported the overexpression of pepsinogen C in hepatocellular carcinoma, 14 and our results are the first to demonstrate the correlation between PGA and HCC.…”

Section: Discussionmentioning

confidence: 57%

New biomarkers and therapeutic targets of human liver cancer: Transcriptomic findings

Huang

et al. 2021

BioFactors

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common causes of cancerrelated deaths worldwide, causing 782,000 deaths in 2018. Poor prognosis and lack of treatment are the reasons for the high mortality rate of HCC. In the current study, we conducted a comparative transcriptomic analysis, followed by a series of bioinformatics analyses, including Gene Ontology (GO) enrichment analysis and Ingenuity Pathway Analysis (IPA), aiming to unfold the detailed molecular mechanisms underlying the development of HCC. In the comparative transcriptomic analysis of 10 pairs of HCC tumoral tissues and adjunct nontumoral tissues, we identified 115 common differentially expressed genes in HCC. The GO enrichment analysis of these genes highlighted alterations in the immune response, cell proliferation and DNA damage, energetic metabolism, cell-matrix adhesion, and filament assembly in HCC. In addition, the canonical pathway analysis of IPA further showed the importance of many cell-signaling pathways involved in the carcinogenesis of HCC. The findings of this study provide a cluster of novel biomarkers and molecular therapeutic targets for HCC diagnosis and treatment.

show abstract

“…PGA5 was associated with good prognosis of cancer patients such as kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma, while lung squamous cell carcinoma, prostate adenocarcinoma, and endometrial carcinoma are associated with poor prognosis of cancer patients. Previous studies have shown that PGC expression and tumor size are independent prognostic factors for overall survival and disease‐free survival in hepatocellular carcinoma 29 . PGC was also an important prognostic factor in predicting longer survival of patients with prostate adenocarcinoma 30 .…”

Section: Discussionmentioning

confidence: 85%

“…Previous studies have shown that PGC expression and tumor size are independent prognostic factors for overall survival and disease-free survival in hepatocellular carcinoma. 29 PGC was also an important prognostic factor in predicting longer survival of patients with prostate adenocarcinoma. 30 Our findings suggest that PGC and PGA5 had different effects on the prognosis of many kinds of cancers and they may be used as predictors of the prognosis in different cancers.…”

Section: Discussionmentioning

confidence: 93%

The panoramic picture of pepsinogen gene family with pan‐cancer

Shen

Liu

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Background It is well known that pepsinogen (PGs), as an important precursor of pepsin performing digestive function, has a good correlation with the occurrence and development of gastric cancer and it is also known that ectopic PGs expression is related to the prognosis of some cancers. However, the panoramic picture of pepsinogen gene family in human cancer is not clear. This study focused on elucidating the expression profile, activated pathway, immune cells infiltration, mutation, and copy number variation of PGs and their potential role in human cancer. Method Based on the next generation sequence data from TCGA, Oncomine, and CCLE, the molecular changes and clinical correlation of PGs in 33 tumor types were analyzed systematically by R language, including the expression, mutation, and copy number variation of PGs and their correlation with cancer‐related signal transduction pathway, immune cell infiltration, and prognostic potential in different cancers. Results PGs expression profiles appear different in 33 tumors. The transcriptional expression of PGs was detected in 16 of all 33 tumors. PGC was highly expressed in cholangiocarcinoma, colon adenocarcinoma, rectum adenocarcinoma, uterine corpus endometrial carcinoma, bladder urothelial carcinoma and breast cancer, while decreased in stomach adenocarcinoma, kidney renal clear cell carcinoma, prostate adenocarcinoma, lung squamous cell carcinoma, and esophageal carcinoma. PGA3, PGA4, and PGA5 were expressed in most normal tissues, but decreased in cancer tissues. PGs expression was significantly related to the activation or inhibition of many signal transduction pathways, in which PGC and PGA5 are more likely to be associated with cancer‐related pathways. PGC participated in 33 regulatory network pathways in pan‐cancer, mainly distributed in stomach adenocarcinoma, esophageal carcinoma, and lung squamous cell carcinoma, respectively. PGC and PGA3 expression were significantly correlated with immune cell infiltration. The results of survival analysis showed that different PGs expression play significantly different prognostic roles in different cancers. PGC was correlated with poor survival in brain lower grade glioma, skin cutaneous melanoma, and higher survival in kidney renal clear cell carcinoma, acute myeloid leukemia, mesothelioma, and uveal melanoma. PGA4 was only associated with higher survival in kidney renal clear cell carcinoma. Genetic variation analysis showed that PGC gene often mutated in uterine corpus endometrial carcinoma and stomach adenocarcinoma had extensive copy number amplification in various tumor types. PGC expression was upregulated with the increase of copy number in cholangiocarcinoma, esophageal carcinoma, and kidney renal papillary cell carcinoma, while in stomach adenocarcinoma, PGC was upregulated regardless of whether the copy number was increased or decreased. Conclusions PGs was expressed unevenly in ...

show abstract

<p>Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study</p>

Cited by 5 publications

References 24 publications

Identification of the Secreted Proteins Originated from Primary Human Hepatocytes and HepG2 Cells

Identification of the Secreted Proteins Originated from Primary Human Hepatocytes and HepG2 Cells

New biomarkers and therapeutic targets of human liver cancer: Transcriptomic findings

The panoramic picture of pepsinogen gene family with pan‐cancer

Contact Info

Product

Resources

About